Open access
Open access
Powered by Google Translator Translator

Dermatology

Cutaneous Lupus Erythematosus | An update on pathogenesis and future therapeutic directions

12 May, 2023 | 13:28h | UTC

Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions – American Journal of Clinical Dermatology

 


RCT | Bacterial decolonization for prevention of radiation dermatitis

8 May, 2023 | 12:46h | UTC

Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

News Release: A Simple Antibacterial Treatment Solves a Severe Skin Problem Caused by Radiation Therapy – Montefiore Einstein Cancer Center

 

Commentary on Twitter

 


Cohort Study | Skin biopsy yields 88% sensitivity in detecting meningococcal Purpura Fulminans

5 May, 2023 | 15:15h | UTC

Skin biopsy in adult patients with meningococcal purpura fulminans: a multicenter retrospective cohort study – Critical Care

 


Review | A practical guide to hidradenitis suppurativa

4 May, 2023 | 13:29h | UTC

A practical guide to hidradenitis suppurativa – Family Practice

 


Differential diagnosis, prevention, and treatment of mpox (Monkeypox): a review for dermatologists

3 May, 2023 | 15:27h | UTC

Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists – American Journal of Clinical Dermatology

Related: Supportive Care Management Recommendations for Mucocutaneous Manifestations of Monkeypox Infection – Mayo Clinic Proceedings

 


Supportive care management recommendations for mucocutaneous manifestations of monkeypox infection

3 May, 2023 | 15:26h | UTC

Supportive Care Management Recommendations for Mucocutaneous Manifestations of Monkeypox Infection – Mayo Clinic Proceedings

Related: Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists – American Journal of Clinical Dermatology

 


Review | Calciphylaxis and kidney disease

3 May, 2023 | 15:20h | UTC

Calciphylaxis and Kidney Disease: A Review – American Journal of Kidney Diseases

 


RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis

3 May, 2023 | 15:04h | UTC

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial – JAMA Dermatology

Commentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live

 

Commentary on Twitter

 


Syphilis in dermatology | Recognition and management

2 May, 2023 | 13:40h | UTC

Syphilis in Dermatology: Recognition and Management – American Journal of Clinical Dermatology

 

Commentary on Twitter

 


USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations

24 Apr, 2023 | 14:07h | UTC

Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA

Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Editorials:

The USPSTF I Statement on Skin Cancer Screening—Not a Disappointment but an Opportunity – JAMA Dermatology

Skin Cancer Screening: The Importance of Identifying High-risk Subgroups and the Need for US-Based Population Research – JAMA

Insufficient Evidence for Screening Reinforces Need for Primary Prevention of Skin Cancer – JAMA Internal Medicine

Patient Page: Screening and Prevention of Skin Cancer – JAMA

Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA

 

Commentary on Twitter

 


RCT | Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata

21 Apr, 2023 | 13:00h | UTC

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Progress in search for alopecia areata treatment for adolescents  – Yale News

 

Commentary on Twitter

 


Podcast | Fungi fun! an in-depth look at tinea infections in children

18 Apr, 2023 | 13:14h | UTC

Fungi Fun! An In-Depth Look at Tinea Infections – The Cribsiders

 


Phase 2 RCT | Dersimelagon in erythropoietic protoporphyrias

17 Apr, 2023 | 13:05h | UTC

Dersimelagon in Erythropoietic Protoporphyrias – News England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCTs | Eczema Care Online behavioral interventions may support self-care for children and young people

12 Apr, 2023 | 13:02h | UTC

Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials – The BMJ

Editorial: How to make Eczema Care Online freely available – The BMJ

News Release: New website helps improve eczema in children and young people – University of Southampton

 


M-A | The efficacy of topical prostaglandin analogs for hair loss

5 Apr, 2023 | 13:20h | UTC

The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis – Frontiers in Medicine

 


RCT | Vitamin D supplementation shows no significant impact on psoriasis severity

4 Apr, 2023 | 13:51h | UTC

Summary: In a randomized, double-blind, placebo-controlled clinical trial involving 122 participants with plaque psoriasis, researchers investigated the effects of vitamin D supplementation on psoriasis severity during winter. Participants received either vitamin D (cholecalciferol, 100,000 IU loading dose followed by 20,000 IU/week) or a placebo for four months. The primary outcome was Psoriasis Area Severity Index (PASI) scores, with secondary outcomes including Physician Global Assessment, self-administered PASI, and Dermatology Life Quality Index scores.

The study found no significant difference in PASI scores or secondary outcomes between the two groups. The results suggest that vitamin D supplementation does not affect psoriasis severity. However, low baseline severity scores and a lower than expected increase in 25-hydroxyvitamin D levels in the intervention group may have influenced the findings, indicating that further research may be needed to account for these factors.

Article: Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial – JAMA Dermatology (free for a limited period)

Commentary: Vitamin D Ineffective for Psoriasis Patients with Lower Serum 25-Hydroxyvitamin D Levels in Winter – HCP Live

 

Commentary on Twitter

 


RCT | Baricitinib + topical corticosteroids effective in kids with moderate-severe atopic dermatitis

4 Apr, 2023 | 13:39h | UTC

Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS) – British Journal of Dermatology

 


S1-guideline cutaneous and subcutaneous leiomyosarcoma

4 Apr, 2023 | 13:37h | UTC

S1-guideline cutaneous and subcutaneous leiomyosarcoma – Journal of the German Dermatology Society

 


Guideline | Merkel cell carcinoma

23 Mar, 2023 | 12:48h | UTC

S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022 – Journal of the German Society of Dermatology

 


Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources

21 Mar, 2023 | 13:29h | UTC

Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources – Dermatology Research and Practice

 


Guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease)

21 Mar, 2023 | 13:27h | UTC

British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022 – British Journal of Dermatology

 


Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis

21 Mar, 2023 | 13:23h | UTC

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University

Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay

 


FDA issues new information on cases of squamous cell carcinoma and lymphomas around breast implants

16 Mar, 2023 | 13:28h | UTC

Summary: The US Food and Drug Administration (FDA) has provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue (capsule) that forms around breast implants. The FDA is aware of 19 cases of SCC in the capsule around the breast implant from published literature, including 3 reports of deaths from the disease.

While the FDA continues to believe that occurrences of SCC in the capsule around the breast implant may be rare, the cause, incidence, and risk factors remain unknown. Health care providers and people who have or are considering breast implants should be aware that cases of SCC and various lymphomas in the capsule around the breast implant have been reported to the FDA and in the literature.

The FDA continues to ask health care providers and people with breast implants to report cases of SCC, lymphomas, or any other cancers around breast implants.

FDA Safety Communication: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants – FDA Safety Communication – U.S. Food & Drug Administration

Commentary: FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants – The ASCO Post

Related:

FDA Report: 660 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Study: Long-term Outcomes of Silicone Breast Implants

 


SR | Therapeutics for treating mpox in humans – still no evidence from randomized trials

15 Mar, 2023 | 15:20h | UTC

Therapeutics for treating mpox in humans – Cochrane Library

Summary: Therapeutics for treating mpox – Cochrane Library

 


RCT | Nirogacestat for desmoid tumors

15 Mar, 2023 | 14:57h | UTC

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Nirogacestat Improves Outcomes for Patients With Desmoid Tumors – Memorial Sloan Kettering Cancer Center

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.